Lasa Supergenerics

Lasa Supergenerics Current Assets

The Current Assets of Lasa Supergenerics (LASA.NS) as of Nov 3, 2026 is 103.46 M INR. In the previous year, Current Assets was 324.64 M INR — a change of -68.13% (lower).

Current Assets

103.46 MINR

YoY

-68.13%

Last updated:

Current Assets of Lasa Supergenerics is 2026 103.46 M INR. Current Assets of Lasa Supergenerics was 2025 324.64 M INR. It decreases by -68.13% lower compared to the previous year.

The Lasa Supergenerics Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2019
859.04 M INR
Jan 1, 2020
759.25 M INR
Jan 1, 2021
643.73 M INR
Jan 1, 2022
686.54 M INR
Jan 1, 2023
462.07 M INR
Jan 1, 2024
414.40 M INR
Jan 1, 2025
324.64 M INR
Jan 1, 2026
103.46 M INR
The Lasa Supergenerics Current Assets history
YEARCurrent AssetsYoY
103.46 MINR-68.13%
324.64 MINR-21.66%
414.40 MINR-10.32%
462.07 MINR-32.70%
686.54 MINR+6.65%
643.73 MINR-15.22%
759.25 MINR-11.62%
859.04 MINR-21.40%
1.09 BINR+22.33%
893.37 MINR—
0.00INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lasa Supergenerics Stock analysis

What does Lasa Supergenerics do? Lasa Supergenerics Ltd manufactures veterinary preparations including API products such as Albendazole, Fenbendazole, Oxfendazole, Providone Iodine, Nitroxylene, Ricobendazole, Halquinol, and others. The company also produces animal feed ingredients like potassium iodide, cobalt sulfate, sodium selenate, ethylediamine dihydroiodide, and vanadyl sulfate, as well as reagents for therapeutic use including cetylpyridinium chloride, bismuth subsalicylate, and sodium selenite. Its manufacturing facility in Mahad and Chiplun, Maharashtra, supports the production of these specialized veterinary and pharmaceutical products. The company's primary customers are likely veterinary pharmaceutical manufacturers and animal health suppliers who require API products, feed additives, and therapeutic reagents. These segments include the veterinary pharmaceutical industry and animal feed production sectors, which rely on Lasa Supergenerics' specialized chemical formulations for their own product lines. The firm's focus on catalyst chemistry and anthelmintic/veterinary API products positions it within the niche market of veterinary pharmaceutical manufacturing. Lasa Supergenerics generates revenue through the sale of its API products, animal feed ingredients, and therapeutic reagents to veterinary and pharmaceutical companies. The company's product portfolio targets the veterinary pharmaceutical sector, where demand for anthelmintic and other API-based solutions is significant. By specializing in catalyst chemistry and producing high-demand veterinary API products, the company serves a specific market segment with tailored chemical solutions. Lasa Supergenerics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lasa Supergenerics stock

Current Assets of Lasa Supergenerics is 103.46 M INR in 2026.

Current Assets of Lasa Supergenerics changed from 324.64 M INR to 103.46 M INR, representing a -68.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Lasa Supergenerics since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Lasa Supergenerics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Lasa Supergenerics

All Key Metrics — Lasa Supergenerics